| __timestamp | Bristol-Myers Squibb Company | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 11947000000 | 21102000000 |
| Thursday, January 1, 2015 | 12651000000 | 28633000000 |
| Friday, January 1, 2016 | 14481000000 | 26129000000 |
| Sunday, January 1, 2017 | 14710000000 | 21736000000 |
| Monday, January 1, 2018 | 16014000000 | 17274000000 |
| Tuesday, January 1, 2019 | 18067000000 | 17774000000 |
| Wednesday, January 1, 2020 | 30745000000 | 20117000000 |
| Friday, January 1, 2021 | 36445000000 | 20704000000 |
| Saturday, January 1, 2022 | 36022000000 | 21624000000 |
| Sunday, January 1, 2023 | 34313000000 | 20618000000 |
| Monday, January 1, 2024 | 36351000000 | 78200000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. From 2014 to 2023, Bristol-Myers Squibb Company and Gilead Sciences, Inc. have showcased intriguing gross profit trajectories. Bristol-Myers Squibb's gross profit surged by approximately 187% over this period, peaking in 2021 with a remarkable 36.4 billion. This growth reflects strategic expansions and successful product launches. In contrast, Gilead Sciences experienced a more modest fluctuation, with a peak in 2015 and a subsequent decline, ending 2023 with a gross profit of 20.6 billion. This represents a 27% decrease from its 2015 high. These trends highlight the dynamic nature of the pharmaceutical sector, where innovation and market adaptation are key. As we delve into these financial narratives, it becomes evident that strategic foresight and adaptability are paramount for sustained success.
Key Insights on Gross Profit: Johnson & Johnson vs Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and GSK plc: A Detailed Gross Profit Analysis
Key Insights on Gross Profit: Bristol-Myers Squibb Company vs Biogen Inc.
Bristol-Myers Squibb Company vs United Therapeutics Corporation: A Gross Profit Performance Breakdown
Bristol-Myers Squibb Company vs Ascendis Pharma A/S: A Gross Profit Performance Breakdown
Who Generates Higher Gross Profit? Bristol-Myers Squibb Company or Veracyte, Inc.
Gilead Sciences, Inc. vs Viatris Inc.: A Gross Profit Performance Breakdown
Key Insights on Gross Profit: Gilead Sciences, Inc. vs Halozyme Therapeutics, Inc.
Gross Profit Trends Compared: Gilead Sciences, Inc. vs Lantheus Holdings, Inc.
Key Insights on Gross Profit: Gilead Sciences, Inc. vs Amphastar Pharmaceuticals, Inc.
Key Insights on Gross Profit: Gilead Sciences, Inc. vs Travere Therapeutics, Inc.
Gross Profit Trends Compared: Gilead Sciences, Inc. vs MiMedx Group, Inc.